RINVOQ Abbvie Pty Ltd
Product name
RINVOQ
Sponsor
Accepted date
Jan-2026
Active ingredients
upadacitinib hemihydrate
Proposed indication
RINVOQ (upadacitinib) is proposed as a treatment for adults with giant cell arteritis, an autoimmune condition that causes inflammation of the arteries and can cause permanent blindness if untreated.
Application type
C (new indication)
Publication date
Jan-2026